Last reviewed · How we verify

Intracoronary injection of stem cell

SCARM Institute, Tabriz, Iran · Phase 1 active Biologic Quality 0/100

Intracoronary injection of stem cell is a Biologic drug developed by SCARM Institute, Tabriz, Iran. It is currently in Phase 1 development.

At a glance

Generic nameIntracoronary injection of stem cell
SponsorSCARM Institute, Tabriz, Iran
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intracoronary injection of stem cell

What is Intracoronary injection of stem cell?

Intracoronary injection of stem cell is a Biologic drug developed by SCARM Institute, Tabriz, Iran.

Who makes Intracoronary injection of stem cell?

Intracoronary injection of stem cell is developed by SCARM Institute, Tabriz, Iran (see full SCARM Institute, Tabriz, Iran pipeline at /company/scarm-institute-tabriz-iran).

What development phase is Intracoronary injection of stem cell in?

Intracoronary injection of stem cell is in Phase 1.

Related